Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Around 15% of colorectal cancers (CRCs) show microsatellite instability (MSI) due to dysfunction of the mismatch repair system (MMR). As a consequence of this, MSI tumours tend to accumulate errors in mononucleotide repeats as those in genes implicated in repairing double-strand breaks (DSBs). Previous studies have shown that irinotecan (CPT-11), a chemotherapy agent inducing DSB, is more active in MSI than in microsatellite stable (MSS) CRC. The purpose of this study was to compare the sensitivity to CPT-11 in a series of CRC cell lines with either proficient or deficient MMR and to assess the mutational status of two DSB repair genes, MRE11 and RAD50, in these cell lines. hMLH1-deficient cell lines due to either epigenetic silencing or mutation showed very similar IC(50) and were four- to nine-fold more sensitive to CPT-11 than the MSS line. Cell lines harbouring mutations in both MRE11 and RAD50 were most sensitive to CPT-11. We conclude that MSI cell lines display higher sensitivity to CPT-11 than MSS cells. Mutation of MRE11 and RAD50 could account for this difference in response to CPT-11. Future clinical trials tailoring chemotherapy regimens based on microsatellite status are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“The current evidence in the treatment of advanced CRC patients shows that multiagent chemotherapy incorporating either oxaliplatin (de Gramont et al, 2000; Giacchetti et al, 2000) or CPT-11 (Douillard et al, 2000; Saltz et al, 2000) onto a backbone of”
BackgroundDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“The current evidence in the treatment of advanced CRC patients shows that multiagent chemotherapy incorporating either oxaliplatin (de Gramont et al, 2000; Giacchetti et al, 2000) or CPT-11 (Douillard et al, 2000; Saltz et al, 2000) onto a backbone of”
BackgroundTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 1×
“…randomised studies have failed to demonstrate that a first-line oxaliplatin combined with infusional 5-FU schedule, or a CPT-11 with infusional 5-FU schedule, was better than the other for the global population of patients with advanced CRC (Giacchetti et al, 2000; Tournigand et al, 2004).”
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160 · cited 1×
“…clinicopathological data (Benatti et al, 2005) as well as two retrospective analysis of clinical trials in the adjuvant setting (Watanabe et al, 2001; Ribic et al, 2003) have suggested that patients with MSI-H may have less sensitivity to 5-FU-based chemotherapy than those with MSI-L/MSS tumours.”
BackgroundKunkel, T. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400006200 · Cited by 754 · cited 1×
“Microsatellites are multiple tandem repeats of a small number of nucleotides that are very prone to these errors; therefore MMR system activity is critical for their maintenance (Kunkel, 2004; Jiricny, 2006).”
BackgroundMicrosatellite instability and colorectal cancer prognosis
Benatti, P., Gafà, R., Barana, D., Marino, M., Scarselli, A., Pedroni, M., Maestri, I., Guerzoni, L., Roncucci, L., Menigatti, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1030 · Cited by 379
Cited by
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
Self-citationGenetic prognostic and predictive markers in colorectal cancer
Walther, A., Johnstone, E., Swanton, C., Midgley, R., Tomlinson, I., & Kerr, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2645 · Cited by 705
Baretti, M., & Le, D. T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.004 · Cited by 556
Sinicrope, F. A., & Sargent, D. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1469 · Cited by 309
Microsatellite instability in colorectal cancer
IACOPETTA, B., GRIEU, F., & AMANUEL, B. (2010) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/j.1743-7563.2010.01335.x · Cited by 289
Metadata
- Authors
- Vilar, E., Scaltriti, M., Balmaña, J., Saura, C., Guzman, M., Arribas, J., Baselga, J., & Tabernero, J.
- Venue
- British Journal of Cancer
- Published
- 2008-10-21
- Volume
- 99
- Issue
- 10
- Pages
- 1607-1612
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2163751095
- Cited by
- 88
- References
- 6
- FWCI
- 4.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. https://app.cochat.ai/papers/10.1038/sj.bjc.6604691
- The paper
- Vilar, E., Scaltriti, M., Balmaña, J., Saura, C., Guzman, M., Arribas, J., Baselga, J., & Tabernero, J. (2008). Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604691
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.